The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease

American Journal of Psychiatry

Volumn 170, Issue 9, 2013, Pages 1051-1058

  Lopez, Oscar L ^a   Becker, James T ^a   Chang, Yue Fang ^a   Sweet, Robert A ^a   Aizenstein, Howard ^a   Snitz, Beth ^a   Saxton, Judith ^a   McDade, Eric ^a   Kamboh, Ilyas ^a   DeKosky, Steven T ^a   Reynolds III, Charles F ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDUCATIONAL STATUS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; SCORING SYSTEM; SIDE EFFECT;

EID: 84883693104     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12081046     Document Type: Article

References (41)

1. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: treatment of dementia and its behavioral disturbances: introduction: methods, commentary, and summary. Postgrad Med 2005; (spec no):6-22
2. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-143
3. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C: Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebocontrolled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767-776
4. Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155:1512-1520
5. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ; Alzheimer's Disease Cooperative Study: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271-1278
6. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538
7. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC: Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164:1568-1576, quiz 1623
8. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943
9. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R; DART-AD Investigators: The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomized placebocontrolled trial. Lancet Neurol 2009; 8:151-157
10. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA: Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341
11. Barak Y, Baruch Y, Mazeh D, Paleacu D, Aizenberg D: Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psychiatry 2007; 15:354-356
12. Suh GH, Shah A: Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr 2005; 17:429-441
13. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a 2-year prospective study. Am J Geriatr Psychiatry 2007; 15:416-424
14. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SL, Gurwitz JH, Marras C, Wodchis WP, Mamdani M: Atypical antipsychotic drugs and risk of ischemic stroke: population-based retrospective cohort study. BMJ 2005; 330: 445-448
15. Jin H, Folsom D, Sasaki A, Mudaliar S, Henry R, Torres M, Golshan S, Glorioso DK, Jeste D: Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res 2011; 125:295-299
16. Wooltorton E: Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-1270
17. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R: Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66:1090-1096
18. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS: Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166:583-590
19. Ballard CG, Waite J, Birks J: Atypical antipsychotics for aggression and psychosis in Alzheimer's disease (review). Cochrane Database Syst Rev 2006; CD003476
20. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T: Predictors of disease course in patients with probable Alzheimer's disease. Neurology 1987; 37:1649-1653
21. Lopez OL, Becker JT, Brenner RP, Rosen J, Bajulaiye OI, Reynolds CF 3rd: Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology 1991; 41:906-912
22. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST: Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56:1266-1272
23. Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y: Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005; 62:1601-1608
24. McKhann G, Drachman DA, Folstein MF, Katzman R, Price DL, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
25. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST: Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology 2000; 55: 1854-1862
26. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y: The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease: The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995; 152:1349-1357
27. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
28. Cornelius JR, Fabrega H Jr, Mezzich J, Cornelius MD, Ulrich RF: Characterizing organic mood syndrome, depressed type. Compr Psychiatry 1993; 34:432-440
29. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST: Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2003; 15:346-353
30. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST: Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology 2000; 55:1863-1869
31. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442
32. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975; 32:632-637
33. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572
34. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population-based cohort study. BMJ 2012; 344:e977
35. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71-79
36. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT: Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58:1161-1167
37. Rossom RC, Rector TS, Lederle FA, Dysken MW: Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 2010; 58:1027-1034
38. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B: Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497-1507
39. Oliveria SA, Liperoti R, L'italien G, Pugner K, Safferman A, Carson W, Lapane K: Adverse events among nursing home residents with Alzheimer's disease and psychosis. Pharmacoepidemiol Drug Saf 2006; 15:763-774
40. Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, Bell K, Sano M, Devanand DP, Bylsma F, Lafleche G: Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 1994; 44:2300-2307
41. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST: Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997; 54:969-975